Suchergebnisse - "Stewart, David J"

PubPharm (7)

1

Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer

enthalten in: Future oncology (London, England) | 2020

von Ponce Aix, S. | Talbot, D. | Govindan, R. | +13

2

ABOUND.2L+ : A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC)

enthalten in: Cancer | 2018

von Morgensztern, D. | Cobo, M. | Ponce Aix, S. | +14

3

Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2012

von Pataer, A. | Kalhor, N. | Correa, A. | +37

4

Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells : why randomized trials failed?

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2011

von Tsai, C. | Chen, J. | Stewart, D. | +5

5

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2008

von Heymach, J. | Paz-Ares, L. | De Braud, F. | +12

6

Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms

enthalten in: Cancer treatment reviews | 2007

von Stewart, D. | Chiritescu, G. | Dahrouge, S. | +2

7

Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2004

von Stewart, D. | Tomiak, E. | Shamji, F. | +2

1
[1]